• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

SteadyMed details commercialization plans for Trevyent

October 18, 2016 By Sarah Faulkner

SteadyMedSteadyMed Therapeutics (NSDQ:STDY) today detailed the development of its lead drug candidate, Trevyent (treprostinil sodium), for the treatment of pulmonary arterial hypertension using its PatchPump tech at the Parenteral Drug Assn. Conference in Huntington Beach, Calif.

PatchPump is the 1st single-use, wearable, pre-filled pump and treprostinil will be the 1st drug integrated with the delivery system, according to the San Ramon, Calif.-based company.

The pump uses a self-powered expanding battery actuator, a semi-flexible container, a printer circuit board assembly for controlling the delivery rate, a proprietary infusion set, and an adhesive patch.

Treprostinil is 1 of 2 therapies on the market indicated for pulmonary arterial hypertension and “both require cumbersome and potentially risky manipulation of drug formulations and device programming on an almost daily basis in order for patients to receive their therapy,” the company explained on its poster. SteadyMed avoids this problem by design, since Trevyent is pre-filled and pre-programmed.

The primary drug container is made from a flexible, thermo-formed film that is heat-sealed onto a base plate, according to SteadyMed. The company explained its development plan from compounding and filling the drug container, to assembly and calibration of the patch.

The company also provided stability data, showing that over 18 months of storage the drug was still at 100% of label claim for all 3 strengths.

Upon completion of the industrialization process and pilot-scale production in 2016, the company is aiming for US regulatory submission and approval in 2017.

“Trevyent overcomes many of the limitations of using general use or insulin infusion pumps for PAH therapy,” SteadyMed wrote. “If approved, Trevyent will fulfill an unmet medical need and will be the 1st parenteral product for PAH that has been custom-designed specifically to meet the needs of PAH patients.”

Filed Under: Drug-Device Combinations, Featured, Research & Development Tagged With: Hypertension, SteadyMed Therapeutics

IN CASE YOU MISSED IT

  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
  • Mosanna launches with $80M to support nasal spray for obstructive sleep apnea

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS